AU2017221472B2 - Methods and compounds for restoring mutant p53 function - Google Patents

Methods and compounds for restoring mutant p53 function Download PDF

Info

Publication number
AU2017221472B2
AU2017221472B2 AU2017221472A AU2017221472A AU2017221472B2 AU 2017221472 B2 AU2017221472 B2 AU 2017221472B2 AU 2017221472 A AU2017221472 A AU 2017221472A AU 2017221472 A AU2017221472 A AU 2017221472A AU 2017221472 B2 AU2017221472 B2 AU 2017221472B2
Authority
AU
Australia
Prior art keywords
group
amino
methyl
prop
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017221472A
Other languages
English (en)
Other versions
AU2017221472A1 (en
Inventor
Romyr Dominique
Hongju Li
Binh Vu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PMV Pharmaceuticals Inc
Original Assignee
PMV Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PMV Pharmaceuticals Inc filed Critical PMV Pharmaceuticals Inc
Publication of AU2017221472A1 publication Critical patent/AU2017221472A1/en
Application granted granted Critical
Publication of AU2017221472B2 publication Critical patent/AU2017221472B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017221472A 2016-02-19 2017-02-17 Methods and compounds for restoring mutant p53 function Active AU2017221472B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297450P 2016-02-19 2016-02-19
US62/297,450 2016-02-19
PCT/US2017/018511 WO2017143291A1 (en) 2016-02-19 2017-02-17 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Publications (2)

Publication Number Publication Date
AU2017221472A1 AU2017221472A1 (en) 2018-07-26
AU2017221472B2 true AU2017221472B2 (en) 2023-01-05

Family

ID=59625486

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017221472A Active AU2017221472B2 (en) 2016-02-19 2017-02-17 Methods and compounds for restoring mutant p53 function

Country Status (10)

Country Link
US (4) US10138219B2 (enExample)
EP (1) EP3416638A4 (enExample)
JP (1) JP6956098B2 (enExample)
KR (1) KR102868217B1 (enExample)
CN (2) CN109069481A (enExample)
AU (1) AU2017221472B2 (enExample)
CA (2) CA3010847C (enExample)
IL (2) IL286839B (enExample)
MX (1) MX383904B (enExample)
WO (1) WO2017143291A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6956098B2 (ja) 2016-02-19 2021-10-27 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物
PH12022550707A1 (en) 2019-09-23 2023-03-27 Pmv Pharmaceuticals Inc METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
WO2021231474A1 (en) * 2020-05-12 2021-11-18 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
WO2021262684A1 (en) * 2020-06-22 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
US20230024905A1 (en) * 2020-06-22 2023-01-26 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
EP4167982A4 (en) * 2020-06-22 2024-08-07 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING FUNCTION OF P53 MUTANTS
CN116249689A (zh) * 2020-06-24 2023-06-09 皮姆维制药公司 用于再激活突变p53的化合物的伴随诊断工具
WO2021262483A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
MX2022015793A (es) * 2020-06-24 2023-02-27 Pmv Pharmaceuticals Inc Terapia de combinacion para tratamiento de cancer.
EP4267553A1 (en) 2020-12-24 2023-11-01 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x2 and related products and methods
WO2022213975A1 (en) * 2021-04-08 2022-10-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
TW202322796A (zh) * 2021-08-10 2023-06-16 大陸商北京加科思新藥研發有限公司 靶向p53突變體的化合物
WO2023025324A1 (zh) * 2021-08-27 2023-03-02 杭州紫晶医药科技有限公司 作为p53调节剂的化合物
CN118891041A (zh) 2022-01-27 2024-11-01 皮姆维制药公司 用于恢复突变p53功能的氘代化合物
WO2024017384A1 (zh) * 2022-07-22 2024-01-25 深圳众格生物科技有限公司 恢复p53突变功能的化合物及其应用
WO2024041503A1 (en) * 2022-08-22 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
CN120077047A (zh) * 2022-10-21 2025-05-30 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
WO2024120471A1 (en) * 2022-12-08 2024-06-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting mutant of p53
WO2025031471A1 (zh) * 2023-08-09 2025-02-13 德睿智药(苏州)新药研发有限公司 用于调节p53功能的新型杂环类化合物
CN119350323B (zh) * 2023-10-20 2025-06-13 上海宇道生物技术有限公司 一类靶向p53突变的N-磺酰酰胺含氮稠杂环类化合物及其应用
WO2025242903A1 (en) * 2024-05-24 2025-11-27 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032175A2 (en) * 1998-12-02 2000-06-08 Pfizer Products Inc. METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
US20120258920A1 (en) * 2008-03-13 2012-10-11 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
WO2012175962A1 (en) * 2011-06-20 2012-12-27 Medical Research Council COMPOUNDS FOR USE IN STABILISING p53 MUTANTS
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
CN104672241A (zh) * 2015-01-29 2015-06-03 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
EP1689710A1 (en) 2003-11-25 2006-08-16 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
KR20160067981A (ko) * 2008-04-16 2016-06-14 카로 바이오 아베 신규한 에스트로겐 수용체 리간드
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
PL2410844T3 (pl) 2009-03-27 2016-08-31 Merck Sharp & Dohme Inhibitory replikacji wirusa zapalenia wątroby typu c
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
EP2665707B1 (en) 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US8859780B2 (en) 2011-12-28 2014-10-14 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
US8822689B2 (en) 2012-09-19 2014-09-02 Merial Limited Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
JP6427599B2 (ja) * 2014-05-19 2018-11-21 チャンスー ヘンルイ メディシン カンパニー，リミテッド チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物
JP6956098B2 (ja) 2016-02-19 2021-10-27 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032175A2 (en) * 1998-12-02 2000-06-08 Pfizer Products Inc. METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
US20120258920A1 (en) * 2008-03-13 2012-10-11 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
WO2012175962A1 (en) * 2011-06-20 2012-12-27 Medical Research Council COMPOUNDS FOR USE IN STABILISING p53 MUTANTS
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
CN104672241A (zh) * 2015-01-29 2015-06-03 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 29 May 2019 (2019-05-29), BILBAO, NEREA ET AL: "Two-Dimensional Nanoporous Networks Formed by Liquid-to-Solid Transfer of Hydrogen-Bonded Macrocycles Built from DNA Bases", XP002791700, retrieved from STN *
Dell'acqua M et al (2015) "MediaChrom: Discovering a Class of Pyrimidoindolone-Based Polarity-Sensitive Dyes", Journal of Organic Chemistry, vol. 80, no. 21, pages 10939 - 10954 *
FIANDANESE, V. BOTTALICO, D. MARCHESE, G. PUNZI, A.: "A straightforward synthesis of indole and benzofuran derivatives", TETRAHEDRON, ELSEVIER SIENCE PUBLISHERS, AMSTERDAM, NL, vol. 64, no. 1, 1 November 2007 (2007-11-01), AMSTERDAM, NL , pages 53 - 60, XP022361251, ISSN: 0040-4020, DOI: 10.1016/j.tet.2007.10.100 *
Guo Z et al (2014) "PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene", Blood, vol. 124, no. 11, pages 1777 - 1789 *
Leblanc et al (2002) Homogeneous time-resolved fluorescence assay for identifying p53 interactions with its protein partners, directly in a cellular extract, Analytical Biochemistry, Vol. 308, Issue 2, 2002, Pages 247-254 *
Selivanova et al (2007) "Reactivation of mutant p53: molecular mechanisms and therapeutic potential", Oncogene, vol. 26, no. 15, pages 2243 - 2254 *
Shinohara Y et al (2010) Design of environmentally sensitive fluorescent 2-deoxyguanosine containing arylethynyl moieties: Distinction of thymine base by base-discriminating fluorescent (BDF) probe, Bioorg & Med Chem Ltrs, 20(9), pp2817-20 *
Tolnai GL, et al (2013) "C2-Selective Direct Alkynylation of Indoles", Organic Letters, vol. 15, no. 1, pages 112 - 115 *

Also Published As

Publication number Publication date
CN109069481A (zh) 2018-12-21
CN119161324A (zh) 2024-12-20
US20220213062A1 (en) 2022-07-07
MX383904B (es) 2025-03-14
WO2017143291A1 (en) 2017-08-24
JP6956098B2 (ja) 2021-10-27
EP3416638A4 (en) 2019-07-17
BR112018016890A2 (pt) 2019-02-12
US11339141B2 (en) 2022-05-24
KR20180138200A (ko) 2018-12-28
IL286839B (en) 2022-08-01
AU2017221472A1 (en) 2018-07-26
US20170240525A1 (en) 2017-08-24
MX2018009947A (es) 2019-01-21
US20190119249A1 (en) 2019-04-25
US10640485B2 (en) 2020-05-05
CN119161324B (zh) 2025-10-17
JP2019512465A (ja) 2019-05-16
EP3416638A1 (en) 2018-12-26
CA3215564A1 (en) 2017-08-24
US20210002252A1 (en) 2021-01-07
IL261175A (en) 2018-10-31
IL286839A (en) 2021-10-31
CA3010847A1 (en) 2017-08-24
IL261175B (en) 2021-10-31
KR102868217B1 (ko) 2025-10-14
CA3010847C (en) 2025-09-23
US10138219B2 (en) 2018-11-27

Similar Documents

Publication Publication Date Title
AU2017221472B2 (en) Methods and compounds for restoring mutant p53 function
CN111315735B (zh) 二氢苯并咪唑酮
TW383307B (en) Pyridopyrazine derivatives
JP6835727B2 (ja) Ｉｒａｋ１／４阻害剤としての大環状化合物及びその使用
TW200304808A (en) N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
EP3833439B1 (en) Benzimidazole inhibitors of pad enzymes
CN108602776A (zh) 用作irak抑制剂的杂芳基化合物及其用途
CN108290879A (zh) 用作irak抑制剂的杂芳基化合物及其用途
CA3211347A1 (en) Indazole based compounds and associated methods of use
JPH08507067A (ja) Ｈｉｖ逆転写酵素阻害剤
US11731953B2 (en) Methods and compounds for restoring mutant p53 function
CN112867706A (zh) Masp-2抑制剂和使用方法
TW201817724A (zh) 化合物
EP3510030B1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
TW202241884A (zh) 肽基精胺酸去亞胺酶之抑制劑
BR112018016890B1 (pt) COMPOSTOS PARA RESTAURAR A FUNÇÃO DE p53 MUTANTE E USO DOS REFERIDOS COMPOSTOS
HK40093207A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HK1246287B (zh) 用作irak抑制剂的哒嗪酮类大环化合物及其用途
HK1242303B (zh) 用作irak抑制剂的杂芳基化合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)